PD Dr. med. Karin Jordan

PD Dr. med. Karin Jordan Fachärztin für Innere Medizin, Hämatologie und Onkologie, Zusatzbezeichnung Palliativmedizin Tel. 0345-557-2019 (Sekretariat Frau Susanne Hildebrand) Fax 0345 557 2950 E-Mail: karin.jordan@uk-halle.de Funktion Leitende Oberärztin Leitung der AG Supportive Therapie (Verlinkung) Weiterbildungsermächtigung Palliativmedizin (1/2 Jahr) Klinische Schwerpunkte Sarkome Keimzelltumore Wissenschaftliche Schwerpunkte Supportive Therapie mit Focus chemotherapie-induzierter Übelkeit und Erbrechen Wissenschaftlicher und beruflicher Werdegang 1993 2001 Studium der Humanmedizin, Martin-Luther-Universität Halle-Wittenberg, Fellowship u.a. in Newcastle und San Diego; Promotion im Bereich der Supportivtherapie seit 2000 Klinik für Hämatologie und Onkologie Universitätsklinik Halle, Rotationen St. Bernward Krankenhaus Hildesheim, St. Elisabeth Krankenhaus Halle 2007 Fachärztin für Innere Medizin seit 2008 Associate Chair der AG Supportive Therapie in der AG internistische Onkologie (AIO) der DKG 2009 Habilitation und Ernennung zur Privatdozentin seit 2009 MASCC/ESMO-Boardmember (Multinational Association of Supportive Care in Cancer) der Perugia Consensus Conference on Antiemetic Therapy seit 2009 Stellvertretende Geschäftsführung und Mitglied der Ethikkommission der Martin Luther Universität Halle-Wittenberg 2010 Fachärztin für Innere Medizin, Hämatologie/Onkologie, Zusatzbezeichnung Palliativmedizin seit 2010 Vorstandsmitglied der ASORS (AG Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin) der Deutsche Krebsgesellschaft 2010-2013 Vertreterin für Deutschland der Young Medical Oncologists der ESMO 2013 S3 Leitlinienkoordinatorin Supportive Therapie bei onkologischen PatientInnen 2013 Associate Editor Annals of Oncology Sektion Supportive Care http://annonc.oxfordjournals.org/

Publikationen PD Dr. Karin Jordan Originalarbeiten 1. Califano R, Karamouzis MV, Banerjee S, de Azambuja E, Guarneri V, Hutka M, Jordan K, Kamposioras K, Martinelli E, Corral J, Postel-Vinay S, Preusser M, Porcu L, Torri V. Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): A European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists Committee. Lung Cancer. 2014 16: S0169-5002(14)00131-7. 2. Gralla R, Bosnjak SM, Hontsa A, Balser C, Rizzi C, Rossi G, Borroni ME, Jordan K. A Phase 3 study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy Ann Oncol 2014 7: 1333-9 3. Jahn P, Kuss O, Schmidt H, Bauer A, Kitzmantel M, Jordan K, Krasemann S, Landenberger M. Improvement of pain related self-management for cancer patients through a modular transitional nursing intervention: a cluster randomized multicenter trial Pain. 2014,155:746-755 4. Proskorovsky I, Lewis P, Williams CD, Jordan K, Kyriakou C, Ishak J, Davies FE. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma Health and Quality of Life outcomes 2014,11;12:35-44 5. Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N, Kyriakou C, Williams CD, Peters F, Davies FE. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study Journal of Supportive Care in Cancer 2014,22:417-426 6. Mueller T, Jordan K, Voigt W. Promising cytotoxic activity profile of fermented wheat germ extract (Avemar (R ) in human cancer cell lines Journal of Experimental & Clinical Cancer Research 2011,30:42: 2-7 7. Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ. The NK-1 receptor-antagonist aprepitant in high-dose (HD) chemotherapy (HD melphalan and HD T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination Bone Marrow Transplantation 2011,46:784-9 8. Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll H.-J. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study Journal of Supportive Care in Cancer 2010,18:423-31

9. Jordan K, Wolf HH, Voigt W, Kegel T, Mueller LP, Behlendorf T, Sippel C, Arnold D, Schmoll HJ. Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study Bone Marrow Transplantation 2010,45:1704-1709 10. Jordan K, Grothey A, Pelz T, Lautenschläger C, Franke U, Schöber C, Schmoll HJ. Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting (PCNV) European Journal of Cancer Care 2010,19:603-9 11. Jordan K, Kinitz I, Voigt W, Behlendorf T, Wolf HH, Schmoll HJ. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy European Journal of Cancer 2009,45:1184-7 12. Jahn P, Renz P, Stukenkemper J, Book K, Kuss O, Jordan K, Horn I, Thoke-Colberg A, Schmoll, HJ, Landenberger, M. Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial Journal of Supportive Care in Cancer 2009,17:1543-52 13. Surov A, Jordan K, Buerke M, Arnold D, John E, Spielmann RP, Behrmann C. Port catheter insufficiency: incidence and clinical-radiological correlations Onkologie 2008,31:455-61 14. Jordan K, Hinke A, Grothey A, Voigt W, Arnold, D, Wolf HH, Schmoll HJ. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis Journal of Supportive Care in Cancer 2007,15:1023-1033 15. Wolf HH, Tscherkes A, Jordan K, Sippel C, Frühauf A, Scheler C. Antithrombotic prophylaxis with low-molecular heparin during pregnancy in women presenting with thrombophilic risk factors Archives of Perinatal Medicine 2007,13: 27-28 16. Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment Annals of Oncology 2006,17:1000-1005 17. Surov A., Jordan K., Buerke M., Persing M., Wollschlaeger B., Behrmann C. Atypical pulmonary embolism of port catheter fragments in oncology patients Journal of Supportive Care in Cancer 2006,14:479-483 18. Jordan K, Grothey A, Kegel T, Fibich C, Schöber C, Schmoll HJ. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting Onkologie 2005, 28:88-92 19. Jordan K, Hinke A, Grothey A, Schmoll HJ. Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis Journal of Supportive Care in Cancer 2005,13:26-31

20. Jordan K, Kellner O, Kegel T, Schmoll HJ, Grothey A. Phase II Trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced colorectal cancer Clinical Colorectal Cancer 2004,4:46-50 Internationale konsensusbasierte Leitlinienbeiträge 1. De Wit M, Ortner P, Lipp HP, Sehouli J, Untch M, Ruhnke M, Mayer-Steinacker R, Bokemeyer C, Jordan K. Management of Cytotoxic Extravasation - ASORS Expert Opinion for Diagnosis, Prevention and Treatment Onkologie 2013,36:127-135 2. Schmoll HJ, Cutsem EV, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, Ghazaly HEL, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Annals of Oncology 2012,23:2479-2516 3. Jordan K, Roila F, Molassiotis A, Maranzano E, Clark-Snow RA, Feyer PC. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009 Journal of Supportive Care in Cancer 2011,19:S37-42 4. Grunberg SM, Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, Espersen BT. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art Journal of Supportive Care in Cancer 2011,19:S43-47 5. Feyer PC, Maranzano E, Molassiotis A, Roila F, Clark-Snow RA, Jordan K. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009 Journal of Supportive Care in Cancer 2011,19:S5-14 6. Olver I, Clark-Snow RA, Ballatori E, Espersen BT, Bria E, Jordan K. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential Journal of Supportive Care in Cancer 2011,19:S33-36 7. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference Annals of Oncology 2010, 5:v232-43 8. Schmoll HJ, Jordan K, Huddart R, Laguna MP, Horwich A, Fizazi K, Kataja V. Testicular seminoma: ESMO Clinical Recommendations for diagnosis, treatment and follow up Annals of Oncology 2010,21(suppl_5):iv140-146

9. Schmoll HJ, Jordan K, Huddart R, Laguna MP, Horwich A, Fizazi K, Kataja V. Testicular non- seminoma: ESMO Clinical Recommendations for diagnosis, treatment and follow up Annals of Oncology 2010, 21(suppl_5):iv147-154 10. Emons G, Kimmig R; Uterus Commission of the Gynecological Oncology Working Group (AGO). Collaborators Emons G, Kimmig R, Beckmann MW, Prescher A, Kopp I, Emons G, Böing, Ebert, Harms, Horn, Kölbl, Steiner, Ulrich, Ackermann, Hillemanns, Höckel, Kimmig, Kleine, Köhler, Lampe, Lichtenegger, Loening, Pilch, Rudlowski, Runnebaum, Schmidt, Schneider, Schnürch, Sommer, Strauss, Strnad, Weidner, Weis J, Keller M, Emons G, Beckmann MW, Hänsgen G, Harms W, Schröck R, Feyer P, Jordan K, König K, Mallmann P, Kimmig R, Schmidt D, Horn LC, Hamm B, Reckers B, Paradis K. Interdisciplinary S2k guidelines on the diagnosis and treatment of endometrial carcinoma. Journal of Cancer Research and Clinical Oncology 2009,10:1387-91 11. Schmoll HJ, Jordan K, Huddart R, Laguna MP, Horwich A, Fizazi K, Kataja V. Testicular seminoma: ESMO Clinical Recommendations for diagnosis, treatment and follow up Annals of Oncology 2009,20(suppl_4):iv83-88 12. Schmoll HJ, Jordan K, Huddart R, Laguna MP, Horwich A, Fizazi K, Kataja V. Testicular non- seminoma: ESMO Clinical Recommendations for diagnosis, treatment and follow up Annals of Oncology 2009,20(suppl_4):iv89-96 Übersichtsarbeiten mit Peer Review 1. Schlitt A, Jordan K, Vordermark D, Schwamborn J, Langer T, Thomssen C. Kardiotoxizität onkologischer Therapien Deutsches Ärzteblatt 2014,111:161-168 2. Jordan K, Gralla R, Jahn F, Molassiotis A. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice European Journal of Pharmacology 2014,722:197-202 3. Feyer P, Jahn F, Jordan K. Radiation induced nausea and vomiting European Journal of Pharmacology 2014,722:165-171 4. Darmani N, Jordan K, Rudd A, Warr D. Guest editors Special Volume New vistas in the pharmacology and neurochemistry of diverse causes of nausea and vomiting European Journal of Pharmacology 2014, Vol. 722 5. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies Annals of Oncology 2011,1:30-8

6. Jordan K, Paul S, Heissner K. Prevention of chemotherapy-induced nausea and vomiting associated with cisplatin chemotherapy European Journal of Clinical and Medical Oncology 2010,2:1-5 7. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management Therapeutic Advances in Medical Oncology 2010,2:51-63 8. Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites? The Oncologist 2009,14:1242-51 9. Schmoll HJ, Jordan K. Current treatment standards in high risk testis cancer European Journal of Cancer 2009, 45 (suppl 1):433-35 10. Jordan K, Müller F, Schmoll HJ. Neue antiemetische Strategien nicht nur in der Onkologie Der Internist 2009,50:887-894 11. Jordan K, Behlendorf T, Mueller F, Schmoll HJ. Anthracycline extravasation injuries: management with dexrazoxane Therapeutics and Clinical Risk Management 2009, 5:361-6 12. Voigt W, Jordan K, Schmoll HJ. Advances in the prognosis and treatment of medullary or anaplastic thyroid cancer European Oncology 2008,4:27-30 13. Jordan K, Behlendorf T, Surov A, Kegel T, Maher G, Wolf HH. Venous Access Ports: Frequency and Management of Complications in Oncology Patients Onkologie 2008,31:404-410 14. Voigt W, Jordan K, Schmoll HJ. Advances in the prognosis and treatment of medullary or anaplastic thyroid cancer European Endocrinology 2008,4:66-69 15. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy induced nausea and vomiting: Past, present, and future recommendations The Oncologist 2007,12:1143-1150 16. Jordan K. The Schwartzberg Article reviewed Chemotherapy-induced nausea and vomiting. Great Achievements but Room for improvement. Oncology 2007,21:1018-1019 17. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs Critical Review in Oncology and Hematology 2007,61:162-75

18. Jordan K, Voigt W, Schmoll HJ. Chemotherapy induced nausea and vomiting-a practical treatment approach Deutsche Medizinische Wochenschrift 2006,131:1869-1872 19. Jordan K. Neurokinin-1-receptor antagonists: A new approach in antiemetic therapy Onkologie 2006, 29:39-43 20. Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment European Journal of Cancer 2005,41:199-205 21. Jordan K, Grothe W, Schmoll HJ. Paravasation von Zytostatika: Prävention und Therapie Deutsche Medizinische Wochenschrift 2005,130:33-37 Buchherausgeberschaft 1. Link H, Jordan K, Feyer P. (Editors) Supportivtherapie bei malignen Erkrankungen Onkodin, Online Publikation 2012 2. Aapro M, Jordan K, Feyer P. (Editors) Prevention of nausea and vomiting in cancer patients Pocket books for cancer supportive care Springer Healthcare,London 2011 Buchbeiträge 1. Jordan K, Ortner P, Link H, Kantelhardt EJ. Supportive Maßnahmen bei Therapie mit Zytostatika und zielgerichteten Substanzen In Untsch, Harbeck, Thomssen, Costa (Editors): Colloquium Senologie 2013. Agileum Verlag München 2013: p257-276 2. Jordan K, Feyer C, Ortner P. Prophylaxis and treatment of chemotherapy-induced nausea and vomiting In Davis, Feyer, Ortner, Zimmermann (Editors): Supportive Oncology. Elsevier Saunders Philadelphia 2011. 1.edition:p16-23 3. Jordan K. Stellenwert der Serotonin-Rezeptorantagonisten In Peschel, Lordick (Editors): Therapie-induzierte Nausea und Emesis in der Onkologie. UNI-MED Verlag Bremen-London-Boston 2011. 3.Aufl.:p50-57 (ISBN 978-3-8374-2208-5) 4. Feyer P, Jordan K. Stellenwert der Serotonin-Rezeptorantagonisten In Peschel, Lordick (Editors): Therapie-induzierte Nausea und Emesis in der Onkologie. UNI-MED Verlag Bremen-London-Boston 2011. 3. Aufl.:p85-93 (ISBN 978-3-8374-2208-5)

5. Jordan K. Antiemese In Supportivtherapie in der Onkologie, Hrsg.: Feyer P. und Ortner P. Urban & Vogel, München 2009,pp9-20 6. Grothe W, Jordan K, Wolf H-H. HIV und AIDS (Kapitel 80) In Akutmedizin - die ersten 24 Stunden, 4.Auflage, Hrsg.: C. Madler et al. Elsevier GmbH, München 2009,pp937-944, (ISBN 978-3-437-22511-6) 7. Jordan K, Sippel C, Behlendorf T, Wolf HH, Schmoll HJ. Antiemetic prophylaxis and treatment of chemotherapy-induced nausea and vomiting. In: Cancer Supportive Care, Advances in therapeutic strategies, Edited by Gary H. Lyman and J. Crawford. 2008:p169-187, (ISBN 978-142005289-3) 8. Jordan K, Bokemeyer C, Langenbrake C, Link H. Antiemetische Prophylaxe und Therapie gemäß den MASCC und ASCO Guidelines In: Kurzgefasste interdisziplinäre Leitlinien 2008 der Deutschen Krebsgesellschaft. 2008,p348-354, (ISBN 928-3-88603-932-6) 9. Arnold D, Wolf HH, Jordan K, Schmoll HJ. Klinische Aspekte internistischer Onkologie In Gerok, Huber, Meinertz, Zeidler (Editors): Die Innere Medizin Referenzwerk für den Facharzt. Schattauer Verlag Stuttgart. 11. Aufl. 2007:p1231-1259, (ISBN 978-3-7945-2222-4) 10. Wolf HH, Jordan K, Frühauf A. Preoperative DDVAP-Testing in patients with Willebrand disease Hemophilia Symposium Hamburg 2006, p:280-282 In Scharrer, Schramm (Editors). Springer Verlag Heidelberg 2006, (ISBN 978-3-540-73534-2) 11. Jordan K. Stellenwert der Serotonin-Rezeptorantagonisten In Peschel, Lordick (Editors): Therapie-induzierte Nausea und Emesis in der Onkologie. UNI-MED Verlag Bremen-London-Boston 2006.1. Aufl.:p48-55, (ISBN 3-89599-929-6) 12. Jordan K, Casper J, Aapro MS, Schmoll HJ. Richtlinien zur antiemetischen Therapie Springer Verlag Heidelberg 2006. 4.Aufl.,Band 1:p2132-2161, (ISBN 10 3-540-20657-4) 13. Jordan K, Berdel WE, Schmoll HJ. Prävention und Therapie von Paravasaten Springer Verlag Heidelberg 2006. 4.Aufl.,Band 1:p2248-2266, (ISBN 10 3-540-20657-4) 14. Jordan K, Sänger S. Empfehlungen zur Bewertung messbarer und nichtmessbarer Tumorparameter Springer Verlag Heidelberg 2006. 4.Aufl.,Band 3:p857-859, (ISBN 10 3-540-20657-4) 15. Jordan K, Sänger S. Empfehlungen zur Bewertung der Tumorremission Springer Verlag Heidelberg 2006. 4.Aufl.,Band 3:p860-865, (ISBN 10 3-540-20657-4)

16. Jordan K, Sänger S. Empfehlungen zur Bewertung des Allgemeinzustandes des Patienten Springer Verlag Heidelberg 2006. 4. Aufl.,Band 3:p866-884, (ISBN 10 3-540-20657-4) 17. Sindermann H, Jordan K, Seegenschmiedt MH, Sänger S. Empfehlungen zur Klassifizierung und Graduierung unerwünschter Ereignisse und Therapienebenwirkungen Springer Verlag Heidelberg 2006. 4.Aufl.,Band 3:p885-970, (ISBN 10 3-540-20657-4) 18. Jordan K, Casper J, Aapro MS, Schmoll HJ. Richtlinien zur antiemetischen Therapie Springer Verlag Heidelberg 2006. 4.Aufl.,Band 3:p1015-1019, (ISBN 10 3-540-20657-4) 19. Jordan K, Berdel WE, Schmoll HJ. Prävention und Therapie von Paravasaten Springer Verlag Heidelberg 2006. 4.Aufl.,Band 3:p1025-1034, (ISBN 10 3-540-20657-4) 20. Jordan K. Central origin and psychosomatics of nausea and emesis In M Staritz, G Adler, A Knuth, W Schmiegel, H.-J. Schmoll (Editors): Side- effects of Cancer Chemotherapy on the Gastrointestinal Tract. Pathophysiology, Prophylaxis and Therapy. Kluwer Academic publishers. Dordrecht, Boston, London, 2003: p113-119 (ISBN 0-7923-8791-0) Elektronische Veröffentlichungen 1. Feyer P, Jordan K. Radiotherapy induced nausea and vomiting, UpToDate, Version updated on 12.6.2013, www.uptodate.com 2. Editors: Link H, Jordan K, Feyer P. Supportivtherapie bei malignen Erkrankungen. Prävention und Behandlung von Erkrankungssymptomen und therapiebedingten Nebenwirkungen, http://www.onkodin.de/e6/e38842/e45084/ 3. Feyer P, Jordan K. Radiotherapy induced nausea and vomiting, UpToDate, Version 20.1, 2012, www.uptodate.com 4. Feyer P, Steingräber M, Jordan K. Radiotherapy induced nausea and vomiting, UpToDate, Version 18.2, 2010, www.uptodate.com 5. Jordan K, Feyer P, Ortner P, Link H. Antiemetische Prophylaxe Aktualisierung der MASCC/ESMO Leitlinien 2009, www.onkocme.de